Introduction
Adverse drug reactions (ADRs) is now becoming the 4 th leading cause of deaths in United States surpassing complex diseases such as diabetes, pneumonia, and AIDS [1] . Over two million ADRs are being reported in U.S. annually that sadly results in 100,000 loss of life every year. Furthermore, a significant resource of $136 billion is dedicated to treat complications arised due to ADRs. In fact, the cost of care for attempting to reverse ADRs symptoms is higher than the cost of care for both diabetic and cardiovascular combined. More importantly, a detailed analysis of ADR incidents reveals that approximately 3 to 5% of all in-hospital medication errors are due to "preventable" drug-drug interactions (DDIs) [1] . Therefore, a natural question arises as to why so many preventable DDIs continues to plaque patients and the healthcare system as a whole, the answer is twofold. First, despite the advances made in drug development and safety, clinical trails * Corresponding author Email addresses: ibrahim.abdelaziz@kaust.edu.sa (Ibrahim Abdelaziz), achille@us.ibm.com (Achille Fokoue), hassanzadeh@us.ibm.com (Oktie Hassanzadeh), pzhang@us.ibm.com (Ping Zhang), msadoghi@purdue.edu (Mohammad Sadoghi) often fail to reveal rare toxicity of certain drugs given the limited size and length of these studies. For instance, an average typical trail for any drug is limited to only 1,500 patients for rather a short period of time. Therefore, they fail to show the actual impacts of the drug once offered to millions of patients for much longer period of time. These concerns are further exacerbated as it is well known that adverse reaction increases exponentially when taking four or more drugs simultaneously [1] . Consequently, the rare toxicity of newly developed drugs cannot be established until after the drug becomes widely available in the market. Second, to make the matter worse, healthcare providers often fail to report ADRs because they have a misconception that all severe adverse reactions are already known when a drug is brought to the market [1].
Recently, there is a growing interest in computationally predicting potential DDIs [2, 3, 4, 5, 6, 7, 8] . These approaches are broadly classified as either similarity (e.g., [2, 6, 7] ) or feature-based (e.g., [3] ) DDI predication methods. There are a set of significant challenges and shortcomings that that are mostly overlooked by prior work. We summarize each of these limitations as follows:
Problem 1: Inability to make predictions for newly developed drugs. Prior work either (i) are fundamentally unable
